Lupin’s Nagpur facility gets zero observations from USFDA after pre-approval inspection

17 Nov 2025 Evaluate

United States Food and Drug Administration (USFDA) has completed a product specific Pre-Approval Inspection at Lupin’s Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from November 10 to November 14, 2025, and concluded with zero 483 observations.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×